)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (IRWD) investor relations material
Ironwood Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Strong Q3 results and LINZESS growth lifted FY 2026 sales, revenue and adjusted EBITDA guidance; Q3 adjusted EBITDA reached a record $97.925M.
LINZESS U.S. sales reached $879.753M year to date, exceeding FY 2025 sales; STARS-2 is recruiting as development and debt reduction continue.
Financial highlights
Q3 revenue was $133.0M versus $122.1M YoY; GAAP net income was $59.8M, or $0.36 per basic and diluted share, versus $40.1M.
9M revenue was $352.6M versus $248.4M; GAAP net income was $151.9M versus $26.3M, and adjusted EBITDA was $257.638M versus $127.2M.
Q3 U.S. LINZESS collaboration revenue was $129.902M; total Q3 revenue was $133.0M.
Cash and cash equivalents were $86.4M at September 30, 2026; 9M operating cash flow was $130.8M.
Outlook and guidance
FY 2026 LINZESS U.S. net sales guidance rose to $1.20B–$1.25B from $1.15B–$1.20B, implying >35% YoY growth.
FY 2026 revenue guidance increased to $485M–$510M from $460M–$485M; adjusted EBITDA guidance rose to >$350M from >$310M.
Outlook assumes improved net price and mid-single-digit demand growth; adjusted EBITDA is non-GAAP, with no GAAP net income reconciliation provided due to uncertainty in adjustments.
Subject to trial results, apraglutide regulatory filing is planned for 2029; STARS-2 site expansion targets >100 sites across 22 countries.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Ironwood Pharmaceuticals
- LINZESS growth supports 2024 targets despite a $1.095B acquisition charge.IRWD
Q4 2023 - Turnaround year with robust growth, LINZESS resurgence, and advancing apraglutide toward 2029 NDA.IRWDWells Fargo 21st Annual Healthcare Conference
- Q2 2026 net sales surged 44% as guidance rose, debt was repaid, and pipeline advanced.IRWDQ2 2026
- Apraglutide and LINZESS drive growth, with new trials, debt reduction, and market leadership ahead.IRWDJefferies Global Healthcare Conference 2026
- LINZESS U.S. net sales soared 97% year-over-year, fueling robust revenue and profit growth.IRWDQ1 2026
- Board recommends voting for all proposals, including equity plan amendment and auditor ratification.IRWDProxy filing
- Key votes include director elections, executive pay, equity plan expansion, and auditor ratification.IRWDProxy filing
- 2026 guidance targets $1.125B–$1.175B LINZESS U.S. net sales and >$300M adjusted EBITDA.IRWDQ4 2025
- LINZESS demand grew 13% in Q3 2024, but net sales fell 19% amid pricing headwinds.IRWDQ3 2024
Next Ironwood Pharmaceuticals earnings date
Q4 202626 Feb, 2027
Ironwood Pharmaceuticals
Next Ironwood Pharmaceuticals earnings date
Q4 202626 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Ironwood Pharmaceuticals Inc is a gastrointestinal-focused healthcare company that develops and markets therapies for chronic digestive diseases. The company’s product portfolio includes treatments for irritable bowel syndrome and other gastrointestinal conditions. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.